methyl 5-(fluoromethoxy)pyrazine-2-carboxylate | 1174321-01-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: methyl 5-(fluoromethoxy)pyrazine-2-carboxylate
• 英文别名: 2-Pyrazinecarboxylic acid, 5-(fluoromethoxy)-, methyl ester
• CAS: 1174321-01-7
• 化学式: C₇H₇FN₂O₃
• 分子量: 186.143
• InChiKey: FOQOQVOVRBUKEG-UHFFFAOYSA-N

物化性质

• 沸点：
  273.6±35.0 °C(Predicted)
• 密度：
  1.299±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  61.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 5-(fluoromethoxy)pyrazine-2-carboxylate 在 甲酸 、 potassium carbonate 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 47.0h， 生成 (S)-N-(3-(2-amino-6-(fluoromethyl)-4-methyl-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide
  参考文献：
  名称：

  Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain

  摘要：

  Accumulation of A beta peptides is a hallmark of Alzheimer's disease (AD) and is considered a causal factor in the pathogenesis of AD. beta-Secretase (BACE1) is a key enzyme responsible for producing A beta peptides, and thus agents that inhibit BACE1 should be beneficial for disease-modifying treatment of AD. Here we describe the discovery and optimization of novel oxazine-based BACE1 inhibitors by lowering amidine basicity with the incorporation of a double bond to improve brain penetration. Starting from a 1,3-dihydrooxazine lead 6 identified by a hit-to-lead SAR following HTS, we adopted a pKa lowering strategy to reduce the P-gp efflux and the high hERG potential leading to the discovery of 15 that produced significant A beta reduction with long duration in pharmacodynamic models and exhibited wide safety margins in cardiovascular safety models. This compound improved the brain-to-plasma ratio relative to 6 by reducing P-gp recognition, which was demonstrated by a P-gp knockout mouse model.

  DOI：

  10.1021/acs.jmedchem.8b00002
• 作为产物：
  描述：

  5-羟基吡嗪-2-羧酸甲酯 、 氟甲醇4-甲基苯磺酸酯 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.5h， 生成 methyl 5-(fluoromethoxy)pyrazine-2-carboxylate
  参考文献：
  名称：

  [EN] FUSED AMINODIHYDRO-OXAZINE DERIVATIVES
  [FR] DÉRIVÉS CONDENSÉS D'AMINODIHYDRO-OXAZINE

  摘要：

  通用式（I）或其药用可接受盐或其溶剂的化合物，其中环A是C6-14芳基或类似物，L是-NReCO-或类似物（其中Re是氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基或类似物，Y是单键或类似物，Z是C1-3烷基或类似物，R1和R2各自独立地是氢原子或类似物，R3、R4、R5和R6各自独立地是氢原子、卤素原子或类似物，具有Aβ产生抑制作用或BACE1抑制作用，并且可用作由Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的预防或治疗剂。

  公开号：

  WO2011009898A1

文献信息

• FUSED AMINODIHYDROTHIAZINE DERIVATIVES
  申请人：SUZUKI Yuichi

  公开号：US20090209755A1

  公开（公告）日：2009-08-20

  A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C 6-14 aryl group or the like, L is —NR e CO— or the like (wherein R e is a hydrogen atom or the like), Ring B is a C 6-14 aryl group or the like, X is a C 1-3 alkylene group or the like, Y is a single bond or the like, Z is a C 1-3 alkylene group or the like, R 1 and R 2 are each independently a hydrogen atom or the like, and R 3 , R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  一个由以下通用公式表示的化合物：或其药用可接受的盐或其溶剂化物，其中环A是C6-14芳基或类似物，L是—NReCO—或类似物（其中Re是氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基烯基或类似物，Y是单键或类似物，Z是C1-3烷基烯基或类似物，R1和R2各自独立地是氢原子或类似物，而R3、R4、R5和R6各自独立地是氢原子、卤原子或类似物，具有Aβ产生抑制作用或BACE1抑制作用，并且可用作由Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的预防或治疗剂。
• NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE
  申请人：Motoki Takafumi

  公开号：US20100093999A1

  公开（公告）日：2010-04-15

  A compound represented by the general formula: wherein Ring A is a C 6-14 aryl group or the like, L is —NR L CO— or the like (wherein R L is a hydrogen atom or the like), Ring B is a C 6-14 aryl group or the like, X is a C 1-3 alkylene group or the like, Y is a C 1-3 alkylene group or the like, Z is an oxygen atom or the like, R 1 and R 2 are each independently a hydrogen atom or the like, and R 3 , R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, or a pharmaceutically acceptable salt thereof, or a solvate thereof, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  一个由通式表示的化合物：其中环A是C6-14芳基或类似物，L是—NRLCO—或类似物（其中RL是氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基烯基或类似物，Y是C1-3烷基烯基或类似物，Z是氧原子或类似物，R1和R2分别是独立的氢原子或类似物，R3、R4、R5和R6独立地是氢原子、卤原子或类似物，或其药用可接受盐，或其溶剂化物，具有Aβ产生抑制作用或BACE1抑制作用，并且可用作治疗Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的治疗剂。
• Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β-Secretase (BACE1) Inhibitors via Active Conformation Stabilization
  作者：Kenji Nakahara、Kouki Fuchino、Kazuo Komano、Naoya Asada、Genta Tadano、Tsuyoshi Hasegawa、Takahiko Yamamoto、Yusuke Sako、Masayoshi Ogawa、Chie Unemura、Motoko Hosono、Hisanori Ito、Gaku Sakaguchi、Shigeru Ando、Shuichi Ohnishi、Yasuto Kido、Tamio Fukushima、Deborah Dhuyvetter、Herman Borghys、Harrie J. M. Gijsen、Yoshinori Yamano、Yasuyoshi Iso、Ken-ichi Kusakabe

  DOI：10.1021/acs.jmedchem.8b00011

  日期：2018.7.12

  On the basis of the X-ray analysis and the QM calculation of given dihydro-oxazines, we reasoned that the substituents at the 6-position as well as the 5-fluorine on the oxazine would stabilize a bioactive conformation to increase potency.

  β-分泌酶（BACE1）在阿尔茨海默氏病（AD）患者体内积累的淀粉样β肽的产生中起着至关重要的作用。因此，抑制BACE1被认为是治疗AD的疾病缓解方法。我们的先导性努力导致了细胞有效的1,3-二氢恶嗪6，但它抑制了hERG并显示出高P-gp外排。5-氟恶嗪8的紧密类似物减少了P-gp的流出。进一步在6位引入吸电子基团提高了效能，也减轻了P-gp外排和hERG抑制作用。改用吡嗪，然后优化恶嗪和吡嗪上的取代基，最终在24在低剂量时体内Aβ的强烈降低以及对CYP2D6的抑制作用降低。在给定的二氢恶嗪的X射线分析和QM计算的基础上，我们认为在恶嗪上的6位取代基以及5-氟会稳定生物活性构象以增加效力。
• Fused aminodihydrothiazine derivatives
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US08158620B2

  公开（公告）日：2012-04-17

  A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  该化合物的普遍式表示为：或其药学上可接受的盐或溶剂，其中环A为C6-14芳基或类似物，L为—NReCO—或类似物（其中Re为氢原子或类似物），环B为C6-14芳基或类似物，X为C1-3烷基或类似物，Y为单键或类似物，Z为C1-3烷基或类似物，R1和R2各自独立地为氢原子或类似物，而R3、R4、R5和R6各自独立地为氢原子、卤素原子或类似物。该化合物具有Aβ产生抑制作用或BACE1抑制作用，并可用作预防或治疗由Aβ引起的神经退行性疾病，如阿尔茨海默型痴呆症的药物。
• Fused aminodihydrothiazine derivative
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US08198269B2

  公开（公告）日：2012-06-12

  A compound represented by the general formula: wherein Ring A is a C6-14 aryl group or the like, L is —NRLCO— or the like (wherein RL is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a C1-3 alkylene group or the like, Z is an oxygen atom or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, or a pharmaceutically acceptable salt thereof, or a solvate thereof, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  一种化合物的普遍式表示为：其中环A为C6-14芳基或类似物，L为—NRLCO—或类似物（其中RL为氢原子或类似物），环B为C6-14芳基或类似物，X为C1-3烷基或类似物，Y为C1-3烷基或类似物，Z为氧原子或类似物，R1和R2各自独立地为氢原子或类似物，而R3、R4、R5和R6各自独立地为氢原子、卤素原子或类似物，或其药学上可接受的盐或其溶剂化物，具有Aβ产生抑制作用或BACE1抑制作用，并且可用作治疗由Aβ引起的神经退行性疾病，例如老年痴呆症的治疗剂。